中国免疫学杂志2018，Vol.34Issue(2)：306-309,316,5.DOI:10.3969/j.issn.1000-484X.2018.02.031
HHLA2在恶性肿瘤中的研究进展
Research progress of HHLA2 in malignant tumor
刘春1
作者信息
- 1. 四川省达州市中心医院重症医学科,达州635000
- 折叠
摘要
Abstract
With in-depth study on tumor pathogenesis in recent years,immunotherapy has gained breakthroughs,and Pembrolizumab,Nivolumab and other drugs,which are represented by programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1),have been approved for clinical use.Both human endogenous retrovirus subfamily H long terminal repeat associating protein 2 (HHLA2) and PD-L1 belong to B7 family and are homologous.They are highly expressed in various solid malignant tumors and are very likely to be another significant immunoassay and therapeutic target in succession to PD-L1.Research progress of HHLA2 in malignant tumors will be reviewed.关键词
HHLA2/恶性肿瘤/研究进展Key words
HHLA2/Malignant tumor/Research progress分类
医药卫生引用本文复制引用
刘春..HHLA2在恶性肿瘤中的研究进展[J].中国免疫学杂志,2018,34(2):306-309,316,5.
